Prevalence of established cardiovascular disease in patients with type 2 diabetes mellitus in the UK

Date of ISAC Approval: 
18/07/2019
Lay Summary: 
Acknowledging the results of recent cardiovascular outcomes trials in diabetes patients with superiority of the tested intervention in patients with established cardiovascular disease, we aim to identify the percentage of type 2 diabetes mellitus patients who have established cardiovascular disease in the UK. Our objective is to describe the prevalence of established cardiovascular disease including stroke and TIA (cerebrovascular disease), myocardial infarction, peripheral artery disease, coronary artery disease and heart failure within the cohort of patients with type 2 diabetes in the United Kingdom.
Technical Summary: 
Acknowledging the results of recent cardiovascular outcomes trials in diabetes patients with superiority of the tested intervention in patients with established cardiovascular disease, we aim to identify the percentage of type 2 diabetes mellitus patients who have established cardiovascular disease in the UK. Our objective is to describe the prevalence of established cardiovascular disease including stroke and TIA (cerebrovascular disease), myocardial infarction, peripheral artery disease, coronary artery disease and heart failure within the cohort of patients with type 2 diabetes in the United Kingdom. This is a retrospective database study from the CPRD database. We will analyse data from adults (>/=18 years of age) patients with type 2 diabetes in the UK. There is a one year index period to identify eligible patients and a minimum of one year look back period. All available medical records prior to and including the index date will be examined.
Health Outcomes to be Measured: 
We aim to identify the proportion of patients who have either individual condition: Prevalence of the following diseases within type 2 diabetes Post myocardial infarction Post ischemic stroke/TIA Peripheral artery disease Heart failure Angina pectoris Coronary artery disease Any of the above conditions ("established cardiovascular disease") We will further determine if there are differences in the group of patients with established cardiovascular disease over those without with regards to: Age Gender Kidney function Most recent LDL-cholesterol values Most recent systolic and diastolic blood pressure values Most recent HbA1C Smoking status
Collaborators: 

Dr Dominik Lautsch - Chief Investigator - Merck & Co., Inc.
Dr Dominik Lautsch - Corresponding Applicant - Merck & Co., Inc.
Mr Lingfeng Yang - Collaborator - Merck & Co., Inc.
Dr Tongtong Wang - Collaborator - Merck & Co., Inc.